1/22
08:14 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
1/22
08:14 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
1/22
05:13 am
fold
Amicus downgraded to Hold from Buy at Jefferies
Low
Report
Amicus downgraded to Hold from Buy at Jefferies
1/22
05:13 am
fold
Amicus downgraded to Hold from Buy at Jefferies
Low
Report
Amicus downgraded to Hold from Buy at Jefferies
1/6
07:25 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
1/6
07:25 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
1/5
09:24 am
fold
Amicus downgraded to Neutral from Buy at Guggenheim
Report
Amicus downgraded to Neutral from Buy at Guggenheim
1/5
09:24 am
fold
Amicus downgraded to Neutral from Buy at Guggenheim
Report
Amicus downgraded to Neutral from Buy at Guggenheim
12/29
08:52 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
12/29
08:00 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
12/29
04:23 am
fold
Amicus downgraded to Market Perform from Outperform at Leerink
Low
Report
Amicus downgraded to Market Perform from Outperform at Leerink
12/23
07:06 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.
12/22
08:37 am
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.
12/22
08:33 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
12/22
08:33 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
12/21
08:38 pm
fold
Amicus downgraded to Neutral from Buy at Citi
Low
Report
Amicus downgraded to Neutral from Buy at Citi
12/19
11:17 am
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
12/19
11:16 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
12/19
11:16 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
12/19
11:12 am
fold
Amicus downgraded to Hold from Buy at Needham
Low
Report
Amicus downgraded to Hold from Buy at Needham
12/19
11:12 am
fold
Amicus downgraded to Hold from Buy at Needham
Low
Report
Amicus downgraded to Hold from Buy at Needham
12/19
10:34 am
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.50 price target on the stock, down previously from $21.00.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.50 price target on the stock, down previously from $21.00.
12/19
10:26 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
12/19
09:29 am
fold
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
Low
Report
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
12/17
10:19 am
fold
Rating for FOLD
Low
Report
Rating for FOLD